*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited ("**Stock Exchange**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

MicroPort NeuroScientific Corporation
微創腦科學有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2172)

VOLUNTARY ANNOUNCEMENT
UFO SPARK® SELF-EXPANDING INTRASACCULAR ANEURYSM EMBOLIZATION DEVICE ENTERS THE INNOVATIVE GREEN PATH OF NMPA

This announcement is made by MicroPort NeuroScientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that UFO Spark® Self-Expanding Intrasaccular Aneurysm Embolization Device developed by the Group, has passed the special review application for innovative medical devices of National Medical Products Administration (the "**NMPA**") and entered the special review procedure (the "**Green Path**"). This selection marks the Group's ninth product to be included in the NMPA's special review for innovative medical devices.

The UFO Spark® Self-Expanding Intrasaccular Aneurysm Embolization Device approved for entry into the Green Path is an innovative medical device designed specifically for the treatment of intracranial aneurysms. Leveraging an advanced intrasaccular hemodynamic regulation concept and a unique configuration design, it enables physicians to achieve precise deployment along the central axis of the aneurysm during minimally invasive interventional procedures. Its design is intended to reduce multiple intraoperative adjustments, lower surgery-related risks, improve aneurysm neck coverage, and help protect surrounding branch vessels. Meanwhile, the dual-layer configuration design combines excellent wall apposition and stable support capability, effectively remodeling the intrasaccular hemodynamic environment, promoting intrasaccular thrombosis and aneurysm neck endothelialization, ensuring the patency of the parent artery and adjacent branch vessels, and reducing interference with normal cerebral blood supply.

Intracranial bifurcation aneurysms are a specific subtype of intracranial aneurysms; they are most commonly located at vascular bifurcations, where they are subjected to high blood flow impact forces and exhibit complex morphologies. Common locations include the terminal segment of the internal carotid artery, the bifurcation of the middle cerebral artery, the anterior communicating artery, the top of the basilar artery, the fetal posterior cerebral artery, the origin of the thick posterior inferior cerebellar arteries, and part of pericallosal artery and callosomarginal artery; these account for approximately 26.0% to 50.9% of all intracranial aneurysms (IA). Intracranial bifurcation aneurysms carry a high risk of rupture and are one of the leading causes of spontaneous subarachnoid hemorrhage, accounting for approximately 60% of all ruptured intracranial aneurysms (RIA). The treatment of intracranial bifurcation aneurysms requires complete occlusion of the aneurysm while maintaining the patency of the parent artery and branch vessels, and therefore still presents certain challenges. The emergence of the UFO Spark® Self-Expanding Intrasaccular Aneurysm Embolization Device provides an innovative treatment solution for patients with complex intracranial aneurysms such as wide-necked and bifurcation aneurysms.

The Group is committed to the development and promotion of innovative medical solutions. It currently offers 29 neuro-interventional products covering major diseases such as aneurysms, stenosis, and thrombus extraction. Nine of the Group's products have been included in the NMPA's Green Path for innovative medical devices; the remaining eight are Tubridge® Flow Diverter, Bridge® Rapamycin Target Eluting Vertebral Stent System, Tigertriever® Revascularization Device, Rebridge® Intracranial Stent, StraitPass® Disposable Aspiration Neuroendoscope Device, Nufairy™ Absorbable Coil, Artemis Dream® Self-Expanding Intracranial Rapamycin Eluting Stent System and NuWismen® Liquid Embolic Agent, including three that have already been launched commercially. Another product, the APOLLO Dream® Intracranial Arterial Rapamycin Target Eluting Stent System, has received Breakthrough Device Designation from the U.S. Food and Drug Administration.

There can be no assurance that UFO Spark® Self-Expanding Intrasaccular Aneurysm Embolization Device will eventually be successfully commercialized. Shareholders and potential investors of the Company should exercise caution when investing in the shares of the Company.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 1 September 2026. Trading in the shares of the Company on the Stock Exchange will remain suspended until further notice.

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, 25 November 2026

As of the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.